Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Ann Surg Oncol. 2019 Oct 10;27(1):156–164. doi: 10.1245/s10434-019-07626-y

TABLE 3.

Incomplete-cytoreduction risk score groups applied to derivation and validation cohorts

Risk score Derivation cohort (n = 272)
Validation cohort (n = 264)
Percent CCR2/3 p Value OR CCR2/3 (95% CI) p Value Percent CCR2/3 p Value OR CCR2/3 (95% CI) p Value
Zero 2%
(n = 1/64)
< 0.001 Ref 2%
(n = 1/65)
0.001 Ref
Low (1–2) 13%
(n = 23/177)
9.4
(1.2–71.2)
0.030 12%
(n = 21/169)
9.1
(1.2–69.0)
0.033
High (3–4) 39%
(n = 12/31)
39.8
(4.8–326.1)
0.001 27%
(n = 8/30)
23.3
(2.8–196.7)
0.004